Roth Capital Brokers Lift Earnings Estimates for Alcobra Ltd. (ADHD)
Alcobra Ltd. (NASDAQ:ADHD) – Equities research analysts at Roth Capital raised their Q3 2016 EPS estimates for Alcobra in a research note issued on Thursday. Roth Capital analyst M. Higgins now anticipates that the firm will post earnings of ($0.25) per share for the quarter, up from their previous forecast of ($0.26). Roth Capital has a “Buy” rating and a $8.00 price objective on the stock. Roth Capital also issued estimates for Alcobra’s Q4 2016 earnings at ($0.14) EPS, FY2016 earnings at ($0.78) EPS, Q1 2017 earnings at ($0.12) EPS, Q2 2017 earnings at ($0.12) EPS, Q3 2017 earnings at ($0.13) EPS, Q4 2017 earnings at ($0.14) EPS, FY2017 earnings at ($0.51) EPS, FY2018 earnings at ($0.53) EPS, FY2019 earnings at $0.30 EPS and FY2020 earnings at $0.49 EPS.
Alcobra (NASDAQ:ADHD) last issued its quarterly earnings results on Tuesday, August 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.01.
ADHD has been the topic of several other reports. WBB Securities lowered Alcobra from a “hold” rating to a “sell” rating and lowered their price objective for the company from $5.00 to $4.00 in a research note on Monday, September 12th. Oppenheimer Holdings Inc. lowered Alcobra from an “outperform” rating to a “market perform” rating in a research note on Thursday, September 29th. Jefferies Group reiterated a “buy” rating on shares of Alcobra in a research note on Thursday, August 25th. Cantor Fitzgerald reiterated a “buy” rating and issued a $16.00 price objective on shares of Alcobra in a research note on Wednesday, August 31st. Finally, Goldman Sachs Group Inc. reiterated a “buy” rating on shares of Alcobra in a research note on Thursday, September 1st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $6.47.
Alcobra (NASDAQ:ADHD) opened at 2.65 on Monday. The stock’s 50 day moving average price is $4.55 and its 200 day moving average price is $4.49. Alcobra has a 12 month low of $1.95 and a 12 month high of $8.78. The firm’s market capitalization is $73.04 million.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Fund Advisors increased its position in shares of Alcobra by 1.8% in the second quarter. BlackRock Fund Advisors now owns 361,130 shares of the company’s stock valued at $1,621,000 after buying an additional 6,516 shares during the last quarter. Stifel Financial Corp increased its position in shares of Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock valued at $278,000 after buying an additional 15,800 shares during the last quarter. Palo Alto Investors LLC increased its position in shares of Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock valued at $1,225,000 after buying an additional 18,600 shares during the last quarter. Jefferies Group LLC purchased a new position in Alcobra during the second quarter valued at about $533,000. Finally, VHCP Management LLC increased its position in Alcobra by 28.7% in the second quarter. VHCP Management LLC now owns 623,313 shares of the company’s stock valued at $2,799,000 after buying an additional 138,813 shares in the last quarter. 73.69% of the stock is currently owned by institutional investors and hedge funds.
Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.
Receive News & Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.